Why do generic drugs fail to achieve an adequate market share in Greece? Empirical findings and policy suggestions

T. Balasopoulos, A. Charonis, K. Athanasakis, J. Kyriopoulos, E. Pavi

Open source

DOI
10.1016/j.healthpol.2016.12.011
Published
2017-03
Container
Health Policy
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.healthpol.2016.12.011,
  title = {Why do generic drugs fail to achieve an adequate market share in Greece? Empirical findings and policy suggestions},
  author = {T. Balasopoulos and A. Charonis and K. Athanasakis and J. Kyriopoulos and E. Pavi},
  year = {2017},
  journal = {Health Policy},
  doi = {10.1016/j.healthpol.2016.12.011},
  url = {https://doi.org/10.1016/j.healthpol.2016.12.011}
}

RIS

TY  - JOUR
TI  - Why do generic drugs fail to achieve an adequate market share in Greece? Empirical findings and policy suggestions
AU  - T. Balasopoulos
AU  - A. Charonis
AU  - K. Athanasakis
AU  - J. Kyriopoulos
AU  - E. Pavi
PY  - 2017
JO  - Health Policy
DO  - 10.1016/j.healthpol.2016.12.011
UR  - https://doi.org/10.1016/j.healthpol.2016.12.011
ER  - 

APA

Balasopoulos, T., Charonis, A., Athanasakis, K., Kyriopoulos, J., & Pavi, E. (2017). Why do generic drugs fail to achieve an adequate market share in Greece? Empirical findings and policy suggestions. Health Policy. https://doi.org/10.1016/j.healthpol.2016.12.011

Source records